Document is current
Any future updates will be listed below
-
Authors
Taghaddos, Dana
Mihalache, Andrew https://orcid.org/0000-0002-2692-0759
Huang, Ryan S. https://orcid.org/0000-0002-3404-5376
Popovic, Marko M. https://orcid.org/0000-0002-0370-5968
Chan, Clara C. https://orcid.org/0000-0002-2886-2011
- License Information
-
More Information
Article History
Received: 29 December 2024
Revised: 6 August 2025
Accepted: 1 September 2025
First Online: 9 September 2025
Competing interests
: DT: None; AM: None; RSH: None; MMP: Financial support (to institution)—PSI Foundation, Fighting Blindness Canada; CCC: Consultant—Aequus, Abbvie, Admare Bioinnovations, Allergan Inc., Aurion, Bausch & Lomb, Johnson & Johnson Vision, Kala Ophthalmics, Labtician Ophthalmics Inc., Novartis, Santen Inc., Sun Ophthalmics, Thea, Valeo Pharma. Shareholder—Abbott, Pfizer. Financial support (to institution)—Aurion, Corneat, Claris Bio. Lecture fees—Abbvie, Allergan Inc., Johnson & Johnson Vision, Labtician Ophthalmics Inc., Thea.
: An ethics statement was not required for this study type, no human or animal subjects or materials were used.
